Patient demographics
| . | Value (range or %) |
|---|---|
| Total number of patients | 212 |
| Male/female | 106/106 |
| Median age (range) at dasatinib commencement, y | 53 (20-86) |
| Starting dose in mg, n (%) | |
| 50 | 7 (3) |
| 70 | 4 (2) |
| 80 | 1 (0.5) |
| 100 | 177 (83) |
| 140 | 21 (10) |
| Not available | 2 (1) |
| Line of therapy, n (%) | |
| First | 51 (24) |
| Second | 125 (59) |
| Third | 36 (17) |
| Median follow-up from commencement (range), mo | 27 (4-116) |
| . | Value (range or %) |
|---|---|
| Total number of patients | 212 |
| Male/female | 106/106 |
| Median age (range) at dasatinib commencement, y | 53 (20-86) |
| Starting dose in mg, n (%) | |
| 50 | 7 (3) |
| 70 | 4 (2) |
| 80 | 1 (0.5) |
| 100 | 177 (83) |
| 140 | 21 (10) |
| Not available | 2 (1) |
| Line of therapy, n (%) | |
| First | 51 (24) |
| Second | 125 (59) |
| Third | 36 (17) |
| Median follow-up from commencement (range), mo | 27 (4-116) |